Aging is the primary risk factor for numerous life-threatening diseases and has long been a central focus of biological research. Epigenetic reprogramming, a process that can modulate cell fate and ...
Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression. In gynecological malignancies-including ovarian, cervical, and ...
nChroma Bio Receives Authorization of Clinical Trial Application to Initiate First-in-Human Study for Epigenetic Silencer CRMA-1001 for the Treatment of Chronic Hepatitis B First CTA authorization ...
Understanding the mechanisms of low temperature-induced epigenetic reprogramming may therefore inform cancer treatments. All in all, this research shows that the genome isn't a fixed instruction ...
Epicrispr, a clinical-stage company pioneering gene-modulating therapies, today reported early clinical data from its ongoing first-in-human, open-label study evaluating EPI-321, an investigational ...
The first cell rejuvenation therapy is set to enter clinics, testing if aging cells can be reset to a younger, healthier ...
The US Food and Drug Administration (FDA) has approved a Phase 1 clinical trial from Life Biosciences that aims to help certain eye cells act younger and improve vision in glaucoma and related ...
BOSTON--(BUSINESS WIRE)--nChroma Bio (“nChroma”), a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results